A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial -

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Cardiovascular system disorders | Surgery
Summary
RCT (n=1398) reported that MiStent was non-inferior to Xience for cardiac death, target-vessel myocardial infarction, or revascularisation at 12 months (5.8% vs 6.5%; −0.8%; 95% CI −3.3 to 1.8; p=0.0001). Rate of stent thrombosis was low and did not differ between groups.
UKMi comment
A related commentary discusses these findings in the context of other drug-eluting stents that have shown to be non-inferior but not superior to the Xience everolimus-eluting stent. The author notes that this trial did not have adequate power to assess superiority of the MiStent sirolimus-eluting stent
Related links: Comment